Showing results (171-180 of 247) with videos related to
Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.Clinical Lung Cancer|September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II TrialDavid R Spigel, John D Hainsworth, Emily R Burkett, et al.Breast Cancer Research : BCR|June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseasePeter Schmid, Javier Cortes, Ana Joaquim, et al.The Lancet. Oncology|May 2, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trialHoward A Burris, Takuji Okusaka, Arndt Vogel, et al.Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid TumorsAnthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.British Journal of Cancer|December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid TumorsChristopher J Sweeney, John D Hainsworth, Ron Bose, et al.Pageof 25